AVCT — Avacta Share News
0.000.00%
Last trade - 00:00- £318.31m
- £317.90m
- £0.11m
Presentations of pre|CISION® Platform Candidates
Brief: Avacta Group Announces Phase 1 Study Opening For AVA6103
Phase 1 study opening for AVA6103
PreCISION payload delivery advantage over ADC
Avacta to Participate in Conference March 2026
Appointment of CSO
Brief: Avacta Therapeutics Says Cardiac Dosing Limit Removed In Faridoxorubicin Program
Brief: Avacta Announces US FDA Clearance Of The Investigational New Drug Application For The Second pre|CISION Medicine, FAP-Exatecan
FDA Clearance of IND Application for AVA6103
Year-end trading update
Avacta reports new AVA6103 pharmacology data
Notice of Investor Presentation
Equity fundraise of £16 million
Brief: Avacta H1 Adjusted EBITDA GBP -11.614 Million
Interim Half Year Results 2025
Notice of Interim Results
Shortlisted for AIM Awards Technology of the Year
Avacta completes sale of Coris Bioconcept
Brief: Avacta Group Announces 3.25 Mln Stg Equity Fundraise